Insider Selling: Vericel (NASDAQ:VCEL) Director Sells $113,500.00 in Stock

Vericel Corporation (NASDAQ:VCEL) Director Robert Md Zerbe sold 2,500 shares of Vericel stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $45.40, for a total transaction of $113,500.00. Following the sale, the director owned 32,995 shares of the company’s stock, valued at $1,497,973. The trade was a 7.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Vericel Trading Up 5.5%

Vericel stock traded up $2.84 during mid-day trading on Friday, hitting $54.62. The company had a trading volume of 1,612,332 shares, compared to its average volume of 598,922. The company’s fifty day moving average is $40.74 and its 200-day moving average is $38.80. The company has a market capitalization of $2.80 billion, a price-to-earnings ratio of 116.22 and a beta of 1.08. Vericel Corporation has a 12-month low of $28.95 and a 12-month high of $55.60.

Vericel (NASDAQ:VCEL) last announced its earnings results on Thursday, November 5th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.21. Vericel had a return on equity of 6.91% and a net margin of 7.91%. The firm had revenue of $85.37 million for the quarter, compared to analyst estimates of $77.95 million. During the same quarter last year, the firm posted $0.10 EPS. The business’s revenue was up 26.5% on a year-over-year basis. As a group, sell-side analysts expect that Vericel Corporation will post 0.54 EPS for the current fiscal year.

Wall Street Analyst Weigh In

VCEL has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Vericel in a research note on Thursday, October 29th. Truist Financial set a $65.00 price target on shares of Vericel in a research note on Friday. Canaccord Genuity Group set a $60.00 target price on Vericel in a report on Thursday, July 30th. HC Wainwright lifted their target price on Vericel from $72.00 to $75.00 and gave the company a “buy” rating in a research note on Friday. Finally, TD Cowen boosted their price target on shares of Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Four research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $60.80.

Hedge Funds Weigh In On Vericel

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of Vericel in the second quarter valued at $360,023,000. William Blair Investment Management LLC acquired a new position in shares of Vericel in the second quarter worth $88,662,000. Bank of America Corp DE acquired a new position in Vericel in the 2nd quarter valued at about $45,210,000. Dimensional Fund Advisors LP grew its holdings in shares of Vericel by 3.6% during the first quarter. Dimensional Fund Advisors LP now owns 844,755 shares of the biotechnology company’s stock worth $27,173,000 after buying an additional 29,135 shares in the last quarter. Finally, TimesSquare Capital Management LLC acquired a new position in Vericel in the 2nd quarter valued at $24,463,000.

Key Headlines Impacting Vericel

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Third-quarter revenue rose 26% year over year to $85.4 million, while earnings were $0.27 per share—well above analyst estimates. Net income increased 179% to $14.2 million; the company also cited record MACI sales. Vericel Q3 2026 results and guidance
• Positive Sentiment: Vericel raised its 2026 revenue guidance to $344–$346 million, above the approximately $336 million consensus, and increased its adjusted EBITDA margin guidance to 28%. Vericel Q3 2026 results and guidance
• Positive Sentiment: HC Wainwright raised its price target from $72 to $75 and reaffirmed a Buy rating, signaling continued analyst confidence after the results. HC Wainwright raises Vericel price target
• Negative Sentiment: A separate analysis described VCEL as potentially overvalued relative to its earnings support, a risk if future growth does not justify investor expectations. Analysis of Vericel’s valuation

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.